Two Healthcare Companies and One Micro-Cap Company Register Strong Insider Buying

Flamel Technologies S.A. (ADR) (NASDAQ:FLML) also had two corporate insiders purchase sizable blocks of shares this week. Chairman Craig R. Stapleton acquired 100,000 American Depositary Shares (ADSs) on Monday at a price of $10.39 per ADS, boosting his overall holding to 482,450 units. Each ADS represents one ordinary share. Moreover, Chief Executive Officer Michael S. Anderson purchased 10,000 ADSs on the same day for $9.74 each, which lifted his overall stake to 124,250 ADSs. The freshly-upped stake also includes 50,000 restricted ADSs.

The specialty pharmaceutical company has seen its shares decline by 42% over the past 52 weeks. Nonetheless, the stock has gained 11% over the past month, after Flamel Technologies reported stronger-than-expected fourth-quarter financial results. The France-based pharmaceutical company generated $172.49 million in revenue during 2015, a sizable increase from the mere $11.99 million in 2014 revenue. The exceptional increase was mainly driven by higher sales of Bloxiverz, which resulted from higher volumes due to market share gains, and higher net selling prices. Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, was approved by the FDA in 2013. The company’s top-line results were also positively impacted by the 2015 launch of Vazculep. The number of hedge funds in our system with stakes in Flamel Technologies increased to 14 from 13 during the final quarter of 2015. The funds invested in the pharmaceutical company had accumulated nearly 28% of its outstanding common stock by December 31. Kevin Kotler’s Broadfin Capital reported owning 4.39 million shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML) through the latest round of 13F filings.

Disclosure: None